Pioneering UK Payment Model For Incentivizing Antibiotic Development Meets Major Milestone
Executive Summary
Shionogi and Pfizer are now in commercial discussions after their antibiotics were recommended for use via the UK’s new subscription-style payment model, which will ensure a fixed annual fee is paid to companies regardless of how many prescriptions are issued. The UK is urging other countries to offer similar incentives to help beat global antimicrobial resistance.
You may also be interested in...
Pfizer And Shionogi Form Vanguard In New Subscription Assault On Antibiotic Resistance
Two antibiotics from Pfizer and Shionogi are to be rolled out by the UK’s NHS in a pioneering subscription deal that hopes to encourage antibiotic R&D by delinking payment from volume of use.
EMA Aligns Antibiotics Guideline To Help Facilitate Global Trials
The EU regulator says it supports a globally aligned approach to the development of new antimicrobial medicines.
‘World’s First’ Antibiotic Incentive Scheme Kicks Off In UK
Pharmaceutical companies are being invited to join a pioneering UK “subscription-style” scheme intended to incentivize the development of innovative antibiotics for the most serious diseases.